MeSH term | MeSH ID | Detail |
---|---|---|
Adenoma | D000236 | 40 associated lipids |
Adenocarcinoma | D000230 | 166 associated lipids |
(-)-perillyl alcohol is a lipid of Prenol Lipids (PR) class. The involved functions are known as Cell Cycle Progression, Cell Cycle, Cell Proliferation, Apoptosis and Isoprenylation. (-)-perillyl alcohol often locates in Cytoplasm, Membrane and Plasma membrane. The associated genes with (-)-Perillyl alcohol are JUN gene, Candidate Disease Gene, IL24 gene, BCL2L1 gene and CFB gene. The related experimental models are Transgenic Model.
To understand associated biological information of (-)-Perillyl alcohol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
There are no associated biomedical information in the current reference collection.
We collected disease MeSH terms mapped to the references associated with (-)-Perillyl alcohol
Lipid pathways are not clear in current pathway databases. We organized associated pathways with (-)-Perillyl alcohol through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Pathway name | Related literatures |
---|
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
Transgenic Model are used in the study 'A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer.' (Stratton SP et al., 2010).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
pmid:28594456 | ||||
pmid:28233648 | ||||
pmid:28314870 | ||||
pmid:24125633 | ||||
pmid:29129690 | ||||
pmid:28450161 | ||||
pmid:28044940 | ||||
pmid:27394002 | ||||
pmid:27220072 | ||||
pmid:26475687 | ||||
pmid:25497898 | ||||
pmid:25240714 | ||||
pmid:27325307 | ||||
pmid:27890582 | ||||
pmid: | ||||
Belanger JT | Perillyl alcohol: applications in oncology. | 1998 | Altern Med Rev | pmid:9855569 |
Karlson J et al. | Inhibition of tumor cell growth by monoterpenes in vitro: evidence of a Ras-independent mechanism of action. | 1996 | Anticancer Drugs | pmid:8826611 |
Yeruva L et al. | Perillyl alcohol and methyl jasmonate sensitize cancer cells to cisplatin. | 2010 | Anticancer Drugs | pmid:19820395 |
Samaila D et al. | Monoterpenes enhanced the sensitivity of head and neck cancer cells to radiation treatment in vitro. | 2004 Sep-Oct | Anticancer Res. | pmid:15517920 |
DA Fonseca CO et al. | Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation. | 2013 | Anticancer Res. | pmid:24324108 |
Burke YD et al. | Effects of the isoprenoids perillyl alcohol and farnesol on apoptosis biomarkers in pancreatic cancer chemoprevention. | 2002 Nov-Dec | Anticancer Res. | pmid:12530055 |
Stayrook KR et al. | Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells. | 1998 Mar-Apr | Anticancer Res. | pmid:9615726 |
d'Alessio PA et al. | Skin repair properties of d-Limonene and perillyl alcohol in murine models. | 2014 | Antiinflamm Antiallergy Agents Med Chem | pmid:24160248 |
van Beilen JB et al. | Biocatalytic production of perillyl alcohol from limonene by using a novel Mycobacterium sp. cytochrome P450 alkane hydroxylase expressed in Pseudomonas putida. | 2005 | Appl. Environ. Microbiol. | pmid:15811996 |
Peffley DM et al. | Perillyl alcohol and genistein differentially regulate PKB/Akt and 4E-BP1 phosphorylation as well as eIF4E/eIF4G interactions in human tumor cells. | 2007 | Arch. Biochem. Biophys. | pmid:17601486 |
da Fonseca CO et al. | Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol. | 2008 Jul-Aug | Arch. Immunol. Ther. Exp. (Warsz.) | pmid:18726148 |
D'Alincourt Salazar M et al. | Intranasal administration of perillyl alcohol activates peripheral and bronchus-associated immune system in vivo. | 2014 | Arch. Immunol. Ther. Exp. (Warsz.) | pmid:24257817 |
Imamura M et al. | Perillyl alcohol suppresses antigen-induced immune responses in the lung. | 2014 | Biochem. Biophys. Res. Commun. | pmid:24309112 |
Ren Z et al. | Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells. | 1997 | Biochem. Pharmacol. | pmid:9296357 |
Sundin T et al. | The isoprenoid perillyl alcohol inhibits telomerase activity in prostate cancer cells. | 2012 | Biochimie | pmid:22902867 |
Yamamoto Y et al. | Synthesis of phosphatidylated-monoterpene alcohols catalyzed by phospholipase D and their antiproliferative effects on human cancer cells. | 2008 | Bioorg. Med. Chem. Lett. | pmid:18556205 |
Cornelissen S et al. | Whole-cell-based CYP153A6-catalyzed (S)-limonene hydroxylation efficiency depends on host background and profits from monoterpene uptake via AlkL. | 2013 | Biotechnol. Bioeng. | pmid:23239244 |
Kim D and Ortiz de Montellano PR | Tricistronic overexpression of cytochrome P450cam, putidaredoxin, and putidaredoxin reductase provides a useful cell-based catalytic system. | 2009 | Biotechnol. Lett. | pmid:19458919 |
Jung HJ et al. | Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. | 2012 | Blood | pmid:22294726 |
Yuri T et al. | Perillyl alcohol inhibits human breast cancer cell growth in vitro and in vivo. | 2004 | Breast Cancer Res. Treat. | pmid:15026623 |
Murren JR et al. | Phase I study of perillyl alcohol in patients with refractory malignancies. | 2002 Mar-Apr | Cancer Biol. Ther. | pmid:12170772 |
Bailey HH et al. | A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. | 2004 | Cancer Chemother. Pharmacol. | pmid:15205914 |
Bailey HH et al. | Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. | 2008 | Cancer Chemother. Pharmacol. | pmid:17885756 |
Azzoli CG et al. | A phase I trial of perillyl alcohol in patients with advanced solid tumors. | 2003 | Cancer Chemother. Pharmacol. | pmid:12695855 |
Morgan-Meadows S et al. | Phase I trial of perillyl alcohol administered four times daily continuously. | 2003 | Cancer Chemother. Pharmacol. | pmid:12904896 |
Lluria-Prevatt M et al. | Effects of perillyl alcohol on melanoma in the TPras mouse model. | 2002 | Cancer Epidemiol. Biomarkers Prev. | pmid:12050099 |
Yeruva L et al. | Perillyl alcohol and perillic acid induced cell cycle arrest and apoptosis in non small cell lung cancer cells. | 2007 | Cancer Lett. | pmid:17888568 |
Chung BH et al. | Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells. | 2006 | Cancer Lett. | pmid:16029925 |
Ren Z and Gould MN | Inhibition of ubiquinone and cholesterol synthesis by the monoterpene perillyl alcohol. | 1994 | Cancer Lett. | pmid:8149348 |
Gelb MH et al. | The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. | 1995 | Cancer Lett. | pmid:7767906 |
Shi W and Gould MN | Induction of differentiation in neuro-2A cells by the monoterpene perillyl alcohol. | 1995 | Cancer Lett. | pmid:7656215 |
Stark MJ et al. | Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. | 1995 | Cancer Lett. | pmid:7553603 |
Bardon S et al. | Monoterpenes inhibit proliferation of human colon cancer cells by modulating cell cycle-related protein expression. | 2002 | Cancer Lett. | pmid:12175534 |
Stratton SP et al. | A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer. | 2010 | Cancer Prev Res (Phila) | pmid:20103724 |
Clifford JL and DiGiovanni J | The promise of natural products for blocking early events in skin carcinogenesis. | 2010 | Cancer Prev Res (Phila) | pmid:20103730 |